Compare Aurobindo Pharma with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ELDER PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ELDER PHARMA AUROBINDO PHARMA/
ELDER PHARMA
 
P/E (TTM) x 11.0 -0.2 - View Chart
P/BV x 2.4 0.1 2,365.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AUROBINDO PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ELDER PHARMA
Jun-14
AUROBINDO PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs809380 212.9%   
Low Rs504188 268.1%   
Sales per share (Unadj.) Rs281.1491.2 57.2%  
Earnings per share (Unadj.) Rs41.4-3.2 -1,299.8%  
Cash flow per share (Unadj.) Rs50.914.4 353.1%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.4376.5 53.0%  
Shares outstanding (eoy) m585.8820.54 2,852.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.6 404.0%   
Avg P/E ratio x15.9-89.3 -17.8%  
P/CF ratio (eoy) x12.919.7 65.5%  
Price / Book Value ratio x3.30.8 436.6%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6305,833 6,593.6%   
No. of employees `00017.3NA-   
Total wages/salary Rs m21,3082,179 977.9%   
Avg. sales/employee Rs Th9,500.7NM-  
Avg. wages/employee Rs Th1,229.4NM-  
Avg. net profit/employee Rs Th1,397.9NM-  
INCOME DATA
Net Sales Rs m164,66610,089 1,632.1%  
Other income Rs m1,020257 397.4%   
Total revenues Rs m165,68610,346 1,601.5%   
Gross profit Rs m37,718-792 -4,762.9%  
Depreciation Rs m5,580361 1,544.3%   
Interest Rs m7772,756 28.2%   
Profit before tax Rs m32,380-3,653 -886.4%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m8,183125 6,538.3%   
Profit after tax Rs m24,229-65 -37,075.9%  
Gross profit margin %22.9-7.8 -291.8%  
Effective tax rate %25.3-3.4 -737.6%   
Net profit margin %14.7-0.6 -2,271.6%  
BALANCE SHEET DATA
Current assets Rs m121,8789,240 1,319.0%   
Current liabilities Rs m86,8069,998 868.3%   
Net working cap to sales %21.3-7.5 -283.6%  
Current ratio x1.40.9 151.9%  
Inventory Days Days13046 280.4%  
Debtors Days Days6860 114.1%  
Net fixed assets Rs m81,03710,124 800.5%   
Share capital Rs m586206 284.8%   
"Free" reserves Rs m116,2185,582 2,081.9%   
Net worth Rs m116,8047,734 1,510.4%   
Long term debt Rs m4,5124,889 92.3%   
Total assets Rs m211,05222,882 922.3%  
Interest coverage x42.7-0.3 -13,115.3%   
Debt to equity ratio x00.6 6.1%  
Sales to assets ratio x0.80.4 177.0%   
Return on assets %11.811.8 100.8%  
Return on equity %20.7-0.8 -2,454.8%  
Return on capital %27.422.3 122.6%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m80,727307 26,329.8%   
Fx outflow Rs m34,700125 27,693.8%   
Net fx Rs m46,027181 25,387.1%   
CASH FLOW
From Operations Rs m19,54811,754 166.3%  
From Investments Rs m-19,570-561 3,491.4%  
From Financial Activity Rs m8,642-6,762 -127.8%  
Net Cashflow Rs m8,9224,432 201.3%  

Share Holding

Indian Promoters % 54.1 39.6 136.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 7.5 106.0%  
FIIs % 27.7 16.8 164.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 36.1 28.3%  
Shareholders   69,601 16,479 422.4%  
Pledged promoter(s) holding % 8.6 77.6 11.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS